Incidence of Major Cardiovascular Events in Diabetic Patients With ACS Undergoing Coronary Angioplasty and Treated With Clopidogrel 150 mg Versus 75 mg

Inclusion criteria: * Male or female aged between 18 to 75 years old. * Proven ACS requiring PTCA within 1 week of inclusion. The ACS should be without ST-segment elevation (presence of chest pain with ST-segment or T-wave changes without sustained ST segment elevation) with elevation of cardiac biomarkers of MI (positive troponins). * Coronary angiography showing at least one coronary lesion, whether mono, bi or multi-truncate * Type 2 diabetes confirmed for at least one year * Patient candidate for treatment with Clopidogrel * Informed consent of patients Non-Inclusion Criteria: * Non-consenting patient and/or participating in another clinical study * ACS with ST segment elevation (STEMI) * History of digestive or cerebral bleeding with antiplatelet agents or anticoagulants * Insulin-dependent diabetes mellitus (IDDM) * Diabetic requiring insulin * Patient in cardiogenic shock * Patient under treatment with anti-glycoprotein IIb/IIIa or stopped less than 72 hours prior to inclusion * Previously treated with clopidogrel or thrombolytics * Patients programmed for surgery in less than 6 months * Ischemic stroke less than 6 weeks old * History of haemorrhagic stroke (regardless of time) * Patients under or candidates for Vitamin K antagonist (VKA) * Patients under another antiplatelet agent (Ticlopidine, Prasugrel) * Patients with a contraindication to clopidogrel (hypersensitivity to the active substance or to any of the excipients, severe hepatic impairment, progressive hemorrhagic lesion such as peptic ulcer or intracranial hemorrhage) * Under omeprazole treatment, or considered during the study * Anemia (Hb \<12g/dl) * Thrombocytopenia with less than 100000 cells/mm3 * Serum creatinine greater than 200 μmol/l * Pregnancy and/or breast-feeding * Severe renal impairment Exclusion criteria: * Non-compliance with treatment (treatment compliance \<80%) * AE/SAE requiring cessation of treatment * Planning a CABG * Occurrence of pregnancy during the study